{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T21:48:10Z","timestamp":1766440090281,"version":"3.41.2"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010607","name":"Universit\u00e0 degli Studi di Perugia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010607","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Vet. Sci."],"abstract":"<jats:p>Extraskeletal osteosarcoma (EOS) is a malignant tumor producing bone matrix and\/or chondroid material, without direct attachment to bone or periosteum. In humans and dogs, EOS is highly infiltrating, rapidly growing, often characterized by osteoid deposition and variable ossification, similar to primary skeletal osteosarcoma (SOS). In dogs, EOS arises from visceral and soft tissue locations, occasionally in trauma or foreign body sites, or in granulomas. Few data are currently available on the phenotype of these tumors. The present study aims to assess the expression RUNX2 and Karyopherin alpha-2 in EOS, comparing it with SOS and the data available from the human counterpart. Seventeen cases of canine osteosarcoma (13 EOS and 4 SOS) were retrospectively selected and submitted to immunohistochemistry for RUNX2 and Karyopherin alpha-2. Our results showed that, in EOS, RUNX2 is expressed in a mean of 73.07 \u00b1 5.36 neoplastic cell nuclei, in face of a mean 36.15 \u00b1 6.25 of Karyopherin alpha-2 positive nuclei. Osteoclasts, when present, were negative for both markers. No correlation was observed among the two markers (<jats:italic>p<\/jats:italic> &amp;gt; 0.05), nor statistically significant difference in quantitative expression was assessed comparing EOS and SOS groups. RUNX2 is expressed in canine EOS similarly to SOS and could be used as a diagnostic marker in a larger panel. Karyopherin alpha-2 is expressed in canine EOS and SOS similarly to human SOS and could be validated in future studies as an additional diagnostic marker. Further studies should be planned to evaluate the expression of these proteins as prognostic predictive parameters.<\/jats:p>","DOI":"10.3389\/fvets.2024.1292852","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T04:42:58Z","timestamp":1706762578000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Canine soft tissue sarcomas: the expression of RUNX2 and karyopherin alpha-2 in extraskeletal (soft tissues) and skeletal osteosarcomas"],"prefix":"10.3389","volume":"11","author":[{"given":"Leonardo","family":"Leonardi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Manuali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonello","family":"Bufalari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Porcellato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-030-90210-0","volume-title":"Bone Tumors in Domestic Animals: Comparative Clinical Pathology","author":"Leonardi","year":"2022"},{"key":"B2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/01.JAA.0000541477.24116.8d","article-title":"Understanding osteosarcomas","volume":"31","author":"Simpson","year":"2018","journal-title":"J Am Acad Physician Assist."},{"volume-title":"Histological Classification of Bone and Joint Tumors of Domestic Animals","year":"1994","author":"Slayter","key":"B3"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1002\/cbin.11673","article-title":"Upregulation of OGT by Calveolin-1 promotes hepatocellular carcinoma cell migration and invasion","volume":"45","author":"Wang","year":"2021","journal-title":"Cell Biol Int"},{"key":"B5","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3390\/vetsci8120307","article-title":"Immunophentyping of an unusual mixed-type extraskeletal osteosarcoma in a dog","volume":"8","author":"Kim","year":"2021","journal-title":"Vet Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1177\/0300985820960131","article-title":"FoxP3, CTLA-4, and IDO in canine melanocytic tumors","volume":"58","author":"Porcellato","year":"2021","journal-title":"Vet Pathol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13000-020-01051-6","article-title":"KPNA2 expression is a potential marker for differential osteosarcomas and other malignant bone tumors mimics","volume":"15","author":"Jiang","year":"2020","journal-title":"Diagn Pathol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1155\/2022\/9973519","article-title":"IRF2 destabilizes oncogenic KPNA2 to modulate the development of osteosarcoma","volume":"22","author":"Xia","year":"2022","journal-title":"J Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"168","DOI":"10.14348\/molcells.2019.0244","article-title":"Molecular mechanism of Runx2-dependent bone development","volume":"43","author":"Komori","year":"2020","journal-title":"Mol Cells."},{"key":"B10","doi-asserted-by":"publisher","first-page":"7001","DOI":"10.3390\/ijms24087001","article-title":"RUNX2 and cancer","volume":"24","author":"Lin","year":"2023","journal-title":"Int J Mol, Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.reth.2021.11.003","article-title":"MiRNA-218 inhibits cell proliferation, migration, and invasion by targeting Runt-related transcription factor 2 (Runx2) in human osteosarcoma line","volume":"18","author":"Guo","year":"2021","journal-title":"Regener Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12935-018-0654-4","article-title":"Novel molecular insights and new therapeutic strategies in osteosarcoma","volume":"18","author":"Otoukesh","year":"2018","journal-title":"Cancer Cell Int."},{"key":"B13","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1177\/03009858221083035","article-title":"The use of alkaline phosphatase and runx2 to distinguish osteosarcoma from other common malignant primary bone tumors in dogs","volume":"59","author":"Barger","year":"2022","journal-title":"Vet Pathol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.bone.2016.10.017","article-title":"Molecular genetics of osteosarcoma","volume":"102","author":"Rickel","year":"2017","journal-title":"Bone."},{"key":"B15","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3892\/ijo.9.2.257","article-title":"Value of immunohistochemical detection of non-collagenous proteins of bone for diagnosis of bone tumours","volume":"9","author":"Serra","year":"1996","journal-title":"Int J Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"13388","DOI":"10.1038\/s41598-017-13353-9","article-title":"MiR-302b suppresses osteosarcoma cell migration and invasion by targeting Runx2","volume":"7","author":"Xie","year":"2017","journal-title":"Sci Rep."},{"key":"B17","doi-asserted-by":"publisher","first-page":"117140","DOI":"10.1016\/j.lfs.2019.117140","article-title":"The emerging roles of KPNA2 in cancer","volume":"241","author":"Han","year":"2020","journal-title":"Life Sci"}],"container-title":["Frontiers in Veterinary Science"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2024.1292852\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T04:43:00Z","timestamp":1706762580000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2024.1292852\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":17,"alternative-id":["10.3389\/fvets.2024.1292852"],"URL":"https:\/\/doi.org\/10.3389\/fvets.2024.1292852","relation":{},"ISSN":["2297-1769"],"issn-type":[{"type":"electronic","value":"2297-1769"}],"subject":[],"published":{"date-parts":[[2024,2,1]]},"article-number":"1292852"}}